ReviewFrontiers in immunology2026
Immune-endothelial-coagulation crosstalk as a driver of multi-organ dysfunction in severe viral pneumonia.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viral burden or pathogen identity alone cannot adequately explain the progression of severe viral pneumonia from a compartmentalized respiratory infection to acute respiratory distress syndrome, multi-organ failure, and death. Maladaptive immunity, endothelial damage, and coagulation dysregulation are all functionally integrated in a host-driven pathological mechanism that mediates disease escalation. Systemic microvascular damage and pulmonary inflammation are linked by immune-endothelial-coagulation interaction. This review investigates the ways in which immunothrombosis and microcirculatory dysfunction are propagated by defective antiviral immunity, alveolar-capillary barrier failure, damage-associated molecular pattern and neutrophil extracellular trap release, endothelial glycocalyx degradation, complement-platelet interactions, coagulation cascade activation, and impaired fibrinolysis. Lung-derived inflammatory signals cause endothelial activation and procoagulant reprogramming in distal organs following systemic dissemination, resulting in organ-specific phenotypes such as acute kidney injury, secondary myocardial injury, ARDS in the lung, neurovascular unit dysfunction, and barrier-disruption-associated inflammatory amplification along the liver-gut axis. This framework may provide a rationale for exploring stage-adapted and phenotype-guided approaches to severe viral pneumonia, including early antiviral therapy, immunomodulation during disease progression, endothelial-coagulation axis targeting, and host-directed strategies. Further longitudinal cohorts, multi-omics analyses, mechanism-based stratification studies, and mechanism-embedded clinical trials will be needed to determine whether immune-endothelial-coagulation coupling can be translated from a mechanistic model into a clinically actionable framework for precision intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.